Bionano Genomics, Inc. reports developments in genome analysis solutions built around optical genome mapping (OGM), diagnostic services, software and nucleic acid extraction technologies. Company updates commonly address OGM applications in cytogenetics, rare disease research, hematologic malignancies, reproductive disorders and other genomic-analysis workflows, including published studies comparing OGM with karyotyping, FISH, chromosomal microarrays, next-generation sequencing and long-read sequencing.
Recurring news also covers financial results, revenue outlooks, scientific-meeting presentations, Bionano Symposium activity, use of VIA™ software, the Ionic® system and Bionano Laboratories diagnostic testing services. Governance updates include board and executive leadership changes at the Nasdaq-listed life sciences instrumentation company.
Bionano Genomics (BNGO) announced a study revealing the efficacy of optical genome mapping (OGM) in investigating hepatocellular carcinoma (HCC). Published in Cancer Research, the research demonstrated OGM's capability to detect replication stress-induced structural variations (SVs) more effectively than whole genome sequencing (WGS). The study found that OGM identified 1.4 times more SVs than WGS, illustrating its potential in understanding oncogenesis mechanisms. CEO Erik Holmlin highlighted OGM's sensitivity for large SV detection, emphasizing its complementary role alongside WGS.
Bionano Laboratories and OptraHEALTH have announced a collaboration to integrate the HealthFAX AI platform to enhance genetic counseling services. This initiative aims to improve patient care by automating educational workflows and providing tailored information on genetic testing. The partnership is expected to increase efficiency and scale operations, allowing Bionano Laboratories to better serve patients seeking genetic diagnostics. Both companies emphasize the importance of reducing anxiety for families awaiting genetic test results through improved access to information and support.
Bionano Genomics (Nasdaq: BNGO) announced the launch of Bionano Laboratories, merging optical genome mapping (OGM) data services with Lineagen's clinical testing services. The newly CLIA-certified lab aims to develop laboratory developed tests (LDTs), starting with a test for facioscapulohumeral muscular dystrophy (FSHD), a key condition in muscular disorder evaluations. This milestone is expected to enhance diagnostic capabilities and facilitate insurance reimbursements for OGM-based assays, aligning with the company's growth strategy.
Bionano Genomics announced a study demonstrating the efficacy of optical genome mapping (OGM) in detecting cryptic balanced chromosomal rearrangements (BCRs) in individuals with recurrent pregnancy loss (RPL). The study involved 11 couples, showing that OGM identified all samples with a 100% concordance to traditional methods like FISH. This highlights OGM's potential as a first-line method for clinical genetic testing, improving detection rates for couples at risk for congenital malformations. CEO Erik Holmlin emphasized the study's importance for patients facing infertility.
Bionano Genomics (Nasdaq: BNGO) has published a new study in Blood Cancer Journal, highlighting the efficiency of Optical Genome Mapping (OGM) for detecting cytogenetic abnormalities in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The study examined 68 patient samples, revealing that OGM identified clinically relevant variants in 33% of MDS and 54% of AML samples, surpassing traditional methods. Key findings suggest OGM's integration into prognostic scoring for myeloid malignancies. This research builds on prior work from MD Anderson Cancer Center.
Bionano Genomics (BNGO) announced a study showcasing the effectiveness of optical genome mapping (OGM) for assessing the quality of hypoimmunogenic induced pluripotent stem cells (iPSCs). This research highlights OGM's ability to detect structural variants in CRISPR-edited cells that traditional methods missed, aiding in genomic integrity evaluation. The study also presents a method to reduce immune rejection risks with CRISPR-Cas9 genome editing. This advancement could enhance iPSC-mediated therapies and improve the safety and efficacy of regenerative medicine applications.
Bionano Genomics (BNGO) will participate virtually in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. A pre-recorded presentation will be accessible on the Company’s Investor Resources page on September 12 at 7:00 am ET. Bionano Genomics focuses on genome analysis solutions, providing optical genome mapping technologies and diagnostic services, including testing for autism spectrum disorder and other neurodevelopmental disabilities. The Company aims to transform genomic research through advanced software and services.
Bionano Genomics (NASDAQ: BNGO) announced the publication of a pioneering study utilizing optical genome mapping (OGM) to investigate the effects of chromothripsis (cth) and TP53 abnormalities in chronic lymphocytic leukemia (CLL) patients with high genomic complexity. The research analyzed 162 CLL patients, confirming OGM's capability to detect cth and its correlation with chromosomal microarray results. While cth was linked to shorter time to first treatment, only TP53 mutations significantly influenced prognosis, indicating that TP53 abnormalities may be the main contributor to adverse outcomes. The study highlights OGM's unique detection power.
Bionano Genomics (Nasdaq: BNGO) has published a groundbreaking study demonstrating the effectiveness of optical genome mapping (OGM) for analyzing repeat expansion disorders. This research highlights OGM's superiority over the traditional Southern blot method, specifically in identifying repeat expansions in the RFC1 gene associated with conditions like CANVAS and adult-onset ataxia. The study screened 626 samples, confirming expanded RFC1 alleles using OGM, which could enhance diagnosis and research accuracy. The company plans to develop more tools for studying complex genetic disorders.
Bionano Genomics (BNGO) reported a record Q2 2022 revenue of $6.7 million, reflecting a 73% year-over-year growth. The company achieved all milestones outlined in its ELEVATE! program. The Saphyr system's installed base increased from 176 to 196, marking a 62% growth year-over-year. Despite the growth, gross margin decreased to 22% due to low yields on consumables. Operating expenses rose significantly, with a GAAP operating expense of $33.6 million. Bionano maintains a strong cash position of $187.3 million and keeps its full-year revenue guidance of $24 million to $27 million.